Academic Journal
View in EDS

COVID-19 vaccine hesitancy in Chinese residents: A national cross-sectional survey in the community setting.

Bibliographic Details
Title: COVID-19 vaccine hesitancy in Chinese residents: A national cross-sectional survey in the community setting.
Authors: Zhao T; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.; Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, P. R. China.; Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, P. R. China., Cai X; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.; Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, P. R. China.; Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, P. R. China., Zhang S; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.; Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, P. R. China.; Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, P. R. China., Wang M; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.; Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, P. R. China.; Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, P. R. China., Chen L; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, USA., Li X; The First Psychiatric Hospital of Harbin, Harbin, Heilongjiang, P. R. China., Wang Z; Dezhou Center for Disease Control and Prevention, Dezhou, Shandong, P. R. China., Wang L; Suzhou Center for Disease Control and Prevention, Suzhou, Anhui, P. R. China., Jiang W; Jining Center for Disease Control and Prevention, Jining, Shandong, P. R. China., Ha Y; Jiuzhaigou Center for Disease Control and Prevention, Aba, Sichuan, P. R. China., Li H; Gansu Provincial Center for Disease Control and Prevention, Laznhou, Gansu, P. R. China., Liu Y; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.; Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, P. R. China.; Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, P. R. China., Lu Q; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.; Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, P. R. China.; Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, P. R. China., Cui F; Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.; Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, P. R. China.; Key Laboratory of Epidemiology of Major Diseases, Ministry of Education, Peking University, Beijing, P. R. China.
Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2481003. Date of Electronic Publication: 2025 Mar 28.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Language: English
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Imprint Name(s): Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience
MeSH Terms: COVID-19 Vaccines*/administration & dosage , Vaccination Hesitancy*/statistics & numerical data , Vaccination Hesitancy*/psychology , COVID-19*/prevention & control , Vaccination Refusal*/statistics & numerical data , Vaccination Refusal*/psychology, China/epidemiology ; SARS-CoV-2/immunology ; Vaccination/psychology ; Vaccination/statistics & numerical data ; Humans ; Cross-Sectional Studies ; Female ; Male ; Adult ; Middle Aged ; Surveys and Questionnaires ; Young Adult ; Aged ; Adolescent ; Vaccination Coverage ; Health Knowledge, Attitudes, Practice ; East Asian People
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine hesitancy is associated with community aggregation, inducing low vaccine coverage and potentially more frequent community-level outbreak. Addressing vaccine hesitancy in community settings should be a priority for healthcare providers. A cross-sectional online questionnaire survey was conducted during June and July 2022. Ten sites were set up in eastern, central, and western China, from where residents were recruited in a community setting. In total, 7,241 residents from 71 communities were included. Of the residents, 7.0% had refusal administration, 30.4% had delayed administration, and community clustering accounted for 2.4-3.7% and 8.5-9.6% of the variation, respectively. The reasons for primary-dose refusal were diseases, pregnancy, or lactation, whereas the main reasons for booster-dose refusal were diseases during the vaccination period, no time to vaccinate, and felt unnecessary to vaccinate. Younger age (under 40), female, residing in urban settings and having self-reported diseases were sociodemographic indicators of risk for refusal. In the health belief model of refusing to vaccinate, perceived barriers had a positive impact on refusal (β = 0.08), while perceived benefits had a negative impact (β = -0.09). In conclusion, this study underscores the population heterogeneity and community clustering of SARS-CoV-2 vaccine hesitancy. Targeted interventions for these high-risk groups are crucial to enhance vaccination coverage and prevent outbreaks. Public health strategies should address vaccine hesitancy at different stages and doses, while considering both individual beliefs and community dynamics.
References: Immunity. 2021 Jul 13;54(7):1611-1621.e5. (PMID: 34166623)
Nat Med. 2021 Aug;27(8):1385-1394. (PMID: 34272499)
Hum Vaccin Immunother. 2021 Sep 2;17(9):2903-2913. (PMID: 34014130)
J Health Commun. 2020 Oct 2;25(10):799-807. (PMID: 33719881)
Vaccine. 2021 May 18;39(21):2833-2842. (PMID: 33896661)
Vaccines (Basel). 2022 Aug 18;10(8):. (PMID: 36016237)
Br J Health Psychol. 2022 Nov;27(4):1354-1381. (PMID: 35642867)
Curr Opin Immunol. 2021 Aug;71:89-91. (PMID: 34271335)
BMJ. 2021 May 20;373:n1138. (PMID: 34016653)
Brain Behav Immun Health. 2021 Mar;12:100204. (PMID: 33495754)
Vaccines (Basel). 2022 Jun 18;10(6):. (PMID: 35746581)
J Educ Health Promot. 2022 Apr 28;11:112. (PMID: 35677278)
Vaccine. 2023 Jan 4;41(1):23-35. (PMID: 36437208)
J Integr Med. 2022 Jan;20(1):34-44. (PMID: 34774463)
Nat Hum Behav. 2021 Mar;5(3):337-348. (PMID: 33547453)
J Multidiscip Healthc. 2022 Jan 11;15:21-45. (PMID: 35046661)
Lancet. 2022 Feb 19;399(10326):699-701. (PMID: 35123665)
Nat Med. 2021 Aug;27(8):1338-1339. (PMID: 34272500)
J Perinatol. 2021 Oct;41(10):2549-2551. (PMID: 34497336)
Int J Environ Res Public Health. 2022 Dec 30;20(1):. (PMID: 36612982)
JMIR Public Health Surveill. 2022 Jan 5;8(1):e29872. (PMID: 34709184)
Clin Infect Dis. 2021 Nov 16;73(10):1784-1789. (PMID: 33560346)
Int J Nurs Stud. 2022 Jul;131:104241. (PMID: 35489108)
Front Immunol. 2021 Nov 29;12:781161. (PMID: 34912346)
Vaccines (Basel). 2022 Mar 29;10(4):. (PMID: 35455277)
Vaccines (Basel). 2021 Feb 16;9(2):. (PMID: 33669441)
Vaccines (Basel). 2021 Oct 13;9(10):. (PMID: 34696281)
Int J Environ Res Public Health. 2021 Jul 29;18(15):. (PMID: 34360345)
Am J Prev Med. 2021 Jan;60(1 Suppl 1):S53-S64. (PMID: 33189500)
Pediatr Clin North Am. 2023 Apr;70(2):359-370. (PMID: 36841602)
Nat Med. 2023 Feb;29(2):366-375. (PMID: 36624316)
Saudi Med J. 2021 Dec;42(12):1341-1352. (PMID: 34853140)
Infect Chemother. 2020 Jun;52(2):154-164. (PMID: 32537961)
BMC Infect Dis. 2022 Feb 14;22(1):153. (PMID: 35164700)
Vaccines (Basel). 2022 Sep 13;10(9):. (PMID: 36146596)
JMIR Mhealth Uhealth. 2021 Dec 27;9(12):e26356. (PMID: 34958306)
Syst Rev. 2022 Apr 26;11(1):78. (PMID: 35473819)
Vaccine. 2022 Apr 14;40(17):2484-2490. (PMID: 34391594)
Sci Adv. 2022 Apr 29;8(17):eabm9825. (PMID: 35476432)
Front Public Health. 2021 Nov 23;9:770985. (PMID: 34888288)
Contributed Indexing: Keywords: COVID-19 vaccine; Vaccine hesitancy; community; cross-sectional study
Local Abstract: [plain-language-summary] Sociodemographic influences: Younger women in urban areas with health conditions were more likely to refuse or delay vaccination.Vaccine hesitancy behaviors in community: We focused on vaccine hesitancy behaviors rather than willingness or confidence, in a large community setting.Clustering of hesitancy: Vaccine hesitancy clustered within communities, with community variation accounting for 2.4%–3.7% for refusal and 8.5%–9.6% for delayed vaccination.Concerns in high-risk groups: We identified a gap between low vaccine acceptance in patients with severe diseases or comorbidities and the prioritization of these groups for vaccination.
Substance Nomenclature: 0 (COVID-19 Vaccines)
Entry Date(s): Date Created: 20250329 Date Completed: 20250515 Latest Revision: 20260901
Update Code: 20260901
PubMed Central ID: PMC11959896
DOI: 10.1080/21645515.2025.2481003
PMID: 40156199
Database: MEDLINE
Description
ISSN:2164-554X
DOI:10.1080/21645515.2025.2481003